J. Viscusi

A phase I pharmacological and pharmacodynamic study of MK-1775, a Wee1 tyrosine kinase inhibitor, in monotherapy and combination with gemcitabine, cisplatin, or carboplatin in patients with advanced solid tumors.

A. Oza, G. Shapiro, J. Schellens, 2010 .

A phase I and pharmacological study of MK-1775, a Wee1 tyrosine kinase inhibitor, in both monotherapy and in combination with gemcitabine, cisplatin, or carboplatin in patients with advanced solid tumors.

A. Oza, G. Shapiro, J. Schellens, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Update on a phase I pharmacologic and pharmacodynamic study of MK-1775, a Wee1 tyrosine kinase inhibitor, in monotherapy and combination with gemcitabine, cisplatin, or carboplatin in patients with advanced solid tumors.

A. Oza, G. Shapiro, J. Schellens, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A Comparison of Cardiovascular Biomarkers in Patients Treated for Three Months with Etoricoxib, Celecoxib, Ibuprofen, and Placebo

C. Cannon, S. Curtis, P. Dibattiste, 2008, Archives of drug information.

Pharmacodynamic evaluation of pCDC2 as the target engagement biomarker to assess activity of MK-1775 a Wee1 tyrosine kinase inhibitor.

A. Oza, G. Shapiro, J. Schellens, 2012 .